Gulf Pain Drugs Market Overview to 2027

0

DUBLIN, July 23, 2021 / PRNewswire / – The report “Gulf Pain Management Drugs Market by Drug Class ,, Indication, Pain Type: Opportunity Analysis and Industry Forecast, 2020-2027” has been added to ResearchAndMarkets.com offer.

The Gulf Pain Management Drugs market has been valued at $ 851.08 million in 2019, and is expected to reach $ 1,047.91 million by 2027, registering a CAGR of 3.2%.

Pain is a distressing sensory and emotional sensation caused by tissue damage or disease. In addition, different disorders can cause discomfort, such as multiple sclerosis, osteoarthritis, stomach ulcer, chronic arthritis, fibromyalgia, diabetic neuropathy, and cancer.

The duration of pain would vary from acute short-term pain to chronic long-term pain. Acute pain is a sudden onset of pain when chronic pain is caused by aged bone and joint conditions, nerve damage, or injury. Pain management involves reducing or treating pain using a specific range of medications. There are several drugs available, which provide pain relief through a variety of physiological mechanisms such as targeting nociceptors.

The increase in the geriatric population is the major factor driving the growth of the Gulf Pain Management Drugs market as the elderly are more likely to suffer from joint pain and other chronic diseases. Additionally, increasing prevalence of chronic diseases, such as cancer, diabetic neuropathy, and osteoarthritis is propelling the market growth. In addition, the increase in the number of surgeries and increase in healthcare expenditure is expected to fuel the growth of the market. However, the exploitation of drugs, the expiration of patents for prescription pain relievers, and the availability of substitutes such as pain relief devices are holding back the growth of the market.

The Gulf Pain Management Drugs market is segmented on the basis of drug class, indication, pain type, and region. On the basis of drug class, the market is categorized into nonsteroidal anti-inflammatory drugs (NSAIDs), anesthetics, anticonvulsants, anti-migraine agents, antidepressants, opioids, and non-narcotic pain relievers. Based on the indication, the market is divided into arthritis pain, neuropathic pain, cancer pain, chronic back pain, postoperative pain, migraine, fibromyalgia, bone fracture, muscle sprain, acute appendicitis, and others. On the basis of pain type, the market is segmented into chronic and acute pain.

The major players operating in the Gulf Pain Management Drugs market are Novartis AG, Eli Lilly & Company, Abbott Laboratories, Pfizer, Inc., Mylan NV., Merck & Co. Inc., Johnson & Johnson, Gulf Pharmaceutical Industries (Julphar), Oman Pharmaceuticals Co. LLC and GlaxoSmithKline Plc.

Key Benefits

  • This report features detailed quantitative analysis along with current Gulf Pain Management Drugs market trends from 2019 to 2027 to identify existing opportunities along with strategic assessment.
  • The market forecast is studied from 2020 to 2027.
  • The market size and estimates are based on a comprehensive analysis of key industry developments.
  • Qualitative analysis based on innovative products facilitates strategic business planning.
  • Development strategies adopted by major market players are mobilized to understand the competitive scenario of the market.

Main topics covered:

Chapter 1 Introduction

Chapter 2: Executive summary

Chapter 3: Market Overview
3.1. Definition and scope of the market
3.2. Main conclusions
3.2.1. Better investment pockets
3.2.2. Best winning strategies
3.3. Positioning of the best players
3.4. Porter’s Five Forces Analysis
3.5. Market dynamics
3.5.1. Conductors
3.5.1.1. Increased incidence of chronic disease
3.5.1.2. Favorable regulatory scenario
3.5.1.3. Increase in the geriatric population
3.5.2. Constraints
3.5.2.1. Availability of alternative therapies
3.5.2.2. Drug exploitation
3.5.2.3. Prescription Drug Patent Expiration
3.5.3. Opportunity
3.5.3.1. Advances in drug development
3.5.4. Impact analysis
3.6. COVID-19 Impact Analysis for Gulf Pain Management Drugs

Chapter 4: Gulf Pain Management Drugs Market, By Drug Class
4.1. Overview
4.1.1. Market size and forecast
4.2. Nonsteroidal anti-inflammatory drugs (NSAIDs)
4.2.1. Key market trends, growth drivers and opportunities
4.2.2. Market size and forecast
4.3. Anesthetics
4.3.1. Key market trends, growth drivers and opportunities
4.3.2. Market size and forecast
4.4. Anticonvulsants
4.4.1. Key market trends, growth drivers and opportunities
4.4.2. Market size and forecast
4.5. Anti-migraine medication
4.5.1. Key market trends, growth drivers and opportunities
4.5.2. Market size and forecast
4.6. Antidepressants
4.6.1. Key market trends, growth drivers and opportunities
4.6.2. Market size and forecast
4.7. Opioids
4.7.1. Key market trends, growth drivers and opportunities
4.7.2. Market size and forecast
4.8. Non-narcotic pain relievers
4.8.1. Key market trends, growth drivers and opportunities
4.8.2. Market size and forecast

Chapter 5: Gulf Pain Management Drugs Market, By Indication
5.1. Overview
5.1.1. Market size and forecast
5.2. Arthritis pain
5.2.1. Market size and forecast
5.3. Neuropathic pain
5.3.1. Market size and forecast
5.4. Cancer pain
5.4.1. Market size and forecast
5.5. Chronic back pain
5.5.1. Market size and forecast
5.6. Postoperative pain
5.6.1. Market size and forecast
5.7. Migraine
5.7.1. Market size and forecast
5.8. Fibromyalgia
5.8.1. Market size and forecast
5.9. Bone fracture
5.9.1. Market size and forecast
5.10. Muscle sprain / strain
5.10.1. Market size and forecast
5.11. Acute appendicitis
5.11.1. Market size and forecast
5.12. Others
5.12.1. Market size and forecast

Chapter 6: Drugs for Pain Management, by Pain Type
6.1. Overview
6.1.1. Market size and forecast
6.2. Chronic pain
6.2.1. Market size and forecast
6.3. Acute pain
6.3.1. Market size and forecast

Chapter 7: Gulf Pain Management Drugs Market, By Country
7.1. Overview
7.1.1. Market size and forecast
7.2. United Arab Emirates
7.2.1. Key market trends and growth opportunities
7.2.2. Market Size and Forecast, by Drug Class
7.2.3. Market size and forecast, by indication
7.2.4. Market Size and Forecast, by Pain Type
7.3. Saudi Arabia
7.3.1. Key market trends and growth opportunities
7.3.2. Market Size and Forecast, by Drug Class
7.3.3. Market size and forecast, by indication
7.3.4. Market Size and Forecast, by Pain Type
7.4. Oman
7.4.1. Key market trends and growth opportunities
7.4.2. Market Size and Forecast, by Drug Class
7.4.3. Market size and forecast, by indication
7.4.4. Market Size and Forecast, by Pain Type
7.5. Rest of the Gulf countries
7.5.1. Key market trends and growth opportunities
7.5.2. Market Size and Forecast, by Drug Class
7.5.3. Market size and forecast, by indication
7.5.4. Market Size and Forecast, by Pain Type

Chapter 8: Company Profiles
8.1. Abbott Laboratories
8.1.1. Company presentation
8.1.2. Company overview
8.1.3. Operational business sectors
8.1.4. Product portfolio
8.1.5. Company performance
8.2. Eli Lily and Company
8.2.1. Company presentation
8.2.2. Company overview
8.2.3. Operational business sectors
8.2.4. Product portfolio
8.2.5. Company performance
8.2.6. Key strategic movements and developments
8.3. GlaxoSmithKline plc (Gsk)
8.3.1. Company presentation
8.3.2. Company overview
8.3.3. Operational business sectors
8.3.4. Product portfolio
8.3.5. Company performance.
8.3.6. Key strategic movements and developments
8.4. Johnson & johnson
8.4.1. Company presentation
8.4.2. Company overview
8.4.3. Operational business sectors
8.4.4. Product portfolio
8.4.5. Company performance
8.5. Merck & Co., Inc.
8.5.1. Company presentation
8.5.2. Company overview
8.5.3. Operational business sectors
8.5.4. Product portfolio
8.5.5. Company performance
8.5.6. Key strategic movements and developments
8.6. Mylan NV
8.6.1. Company presentation
8.6.2. Company overview
8.6.3. Operational business sectors
8.6.4. Product portfolio
8.6.5. Company performance
8.6.6. Key strategic movements and developments
8.7. Novartis International AG
8.7.1. Company presentation
8.7.2. Company overview
8.7.3. Operational business sectors
8.7.4. Product portfolio
8.7.5. Company performance
8.7.6. Key strategic movements and developments
8.8. Pfizer Inc.
8.8.1. Company presentation
8.8.2. Company overview
8.8.3. Operational business sectors
8.8.4. Product portfolio
8.8.5. Company performance
8.8.6. Key strategic movements and developments
8.9. Gulf Pharmaceutical Industries (Julphar)
8.9.1. Company presentation
8.9.2. Company overview
8.9.3. Operational business sectors
8.9.4. Product portfolio
8.9.5. Company performance
8.10. Oman Pharmaceutical Products Co. LLC
8.10.1. Company presentation
8.10.2. Company overview
8.10.3. Operational business sectors
8.10.4. Product portfolio

For more information on this report, visit https://www.researchandmarkets.com/r/7ktclh

Media contact:

Research and markets
Laura Wood, senior
[email protected]

For EST office hours, call + 1-917-300-0470
For USA / CAN call toll free + 1-800-526-8630
For GMT office hours, call + 353-1-416-8900

US Fax: 646-607-1904
Fax (outside the United States): + 353-1-481-1716

SOURCE Research and Markets

Related links

http://www.researchandmarkets.com


Source link

Share.

Leave A Reply